OncoMatch/Clinical Trials/NCT06897488
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
Is NCT06897488 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (positive)
Tumor must be estrogen receptor positive
Required: PR (PGR) overexpression (positive)
Tumor must be ... progesterone receptor positive
Required: HER2 (ERBB2) non-amplified (non-amplified)
HER2Neu non-amplified
Excluded: BRCA1 mutation associated with predisposition to breast cancer development
Known carrier of a mutation associated with predisposition to breast cancer development, including BRCA1 or BRCA2
Excluded: BRCA2 mutation associated with predisposition to breast cancer development
Known carrier of a mutation associated with predisposition to breast cancer development, including BRCA1 or BRCA2
Disease stage
Required: Stage CN0, PN0, PN0(I+)
Pathologic T stage of T1 or T2 with total tumor size ≤ 3cm including any component of DCIS; Clinical nodal stage cN0; If pathologic nodal staging is obtained, then pN0 or pN0(i+); Node positive disease (N1-3) [excluded]; Metastatic disease (M1) [excluded]
Demographics
Prior therapy
Must have received: breast conserving surgery
Treatment with breast conserving surgery
Cannot have received: neoadjuvant therapy
Receipt of neoadjuvant therapy
Cannot have received: radiation therapy
Prior radiotherapy to the index breast or recurrent cancer of the breast
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06897488 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant therapy, radiation therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 non-amplified is a required biomarker for enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation associated with predisposition to breast cancer development is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation associated with predisposition to breast cancer development is an exclusion criterion.
What disease stage is eligible?
Stage CN0 or PN0 or PN0(I+) is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify